This is a $2,234,650 federal contract awarded by the Defense Health Agency to Inhalon Biopharma, Inc., a biopharmaceutical company focused on developing innovative inhaled monoclonal antibody therapies for respiratory infections. The contract is for the development of IN-007, an inhaled treatment using human ACE2 to target and neutralize pathogens. This contract is not set aside for any specific business designation. The work will be conducted at Inhalon's facilities in Morrisville, North Carolina and includes activities such as cell line development, GMP manufacturing, animal studies, and regulatory submissions to support the advancement of IN-007 towards clinical evaluation. Inhalon has also received multiple prior grant awards from the National Institute of Allergy and Infectious Diseases to support the development of its pipeline of inhaled antibody therapies, including treatments for respiratory syncytial virus and human metapneumovirus.
Generated 12/16/24, 2:12 PM